{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:13:49Z","timestamp":1788455629950,"version":"build-2803163510"},"reference-count":80,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinical Research Incubation Project of West China Hospital of Sichuan University","award":["2022HXFH013"],"award-info":[{"award-number":["2022HXFH013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis B virus (HBV) infection is a serious global health problem, and chronic HBV infection significantly increases the risk of liver fibrosis, cirrhosis, and even hepatocellular carcinoma in patients. Current first-line therapeutics such as nucleos(t)ide analogues and interferons are unable to completely clear cccDNA, so the vast majority of patients need to take long-term or even lifelong medication. However, long-term virological and biochemical responses can be achieved in some patients after drug withdrawal. Successfully screening these patients with drug withdrawal advantages is difficult. Hepatitis-B-core-related antigen (HBcrAg) is a new HBV serological marker that which can reflect the level and transcription activity of cccDNA in hepatocytes. Therefore, HBcrAg has potential value in guiding patients in drug withdrawal. This review summarizes previous reports on HBcrAg and evaluates the application value of HBcrAg in safe drug discontinuation.<\/jats:p>","DOI":"10.3390\/v16040529","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T11:11:09Z","timestamp":1712229069000},"page":"529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B"],"prefix":"10.3390","volume":"16","author":[{"given":"Yong-Hong","family":"Wang","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8523-1689","authenticated-orcid":false,"given":"En-Qiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"ref_1","unstructured":"The Polaris Observatory Collaborators (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol. Hepatol., 3, 383\u2013403."},{"key":"ref_2","unstructured":"(2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study. Lancet Gastroenterol. Hepatol., 8, 879\u2013907."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","article-title":"Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: A systematic literature review and meta-analysis of 3740 studies and 231 million people","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"ref_5","unstructured":"Chinese Society of Infectious Diseases, Chinese Medical Association (2019). The expert consensus on clinical cure (functional cure) of chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi, 27, 594\u2013603."},{"key":"ref_6","first-page":"1629","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: A meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"(2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coviro.2018.04.006","article-title":"Perspectives and limitations for nucleo(t)side analogs in future HBV therapies","volume":"30","author":"Levrero","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection: A Review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: Finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","author":"Zoutendijk","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: A systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Allweiss, L., and Dandri, M. (2017). The Role of cccDNA in HBV Maintenance. Viruses, 9.","DOI":"10.3390\/v9060156"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/hep.22930","article-title":"Liver biopsy findings in chronic hepatitis B","volume":"49","author":"Mani","year":"2009","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/gutjnl-2020-321299","article-title":"Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology","volume":"69","author":"Neuberger","year":"2020","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2011.04738.x","article-title":"Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy","volume":"34","author":"Liang","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","author":"Tsuge","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/hepr.13749","article-title":"Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients","volume":"52","author":"Luo","year":"2022","journal-title":"Hepatol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B","volume":"222","author":"Fan","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3350\/cmh.2022.0434","article-title":"Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy","volume":"29","author":"Inoue","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2018.05.047","article-title":"Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy","volume":"17","author":"Chi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","article-title":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective","volume":"52","author":"Jaroszewicz","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.11.003","article-title":"Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity","volume":"74","author":"Suslov","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/gutjnl-2023-330644","article-title":"Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B","volume":"73","author":"Testoni","year":"2024","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12985-020-01471-2","article-title":"Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment","volume":"18","author":"Wang","year":"2021","journal-title":"Virol. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12985-022-01749-7","article-title":"Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B","volume":"19","author":"Laras","year":"2022","journal-title":"Virol. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2018.03.021","article-title":"Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection","volume":"69","author":"Caviglia","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.hpb.2022.06.013","article-title":"The impact of the covalently closed circular DNA level on recurrence of hepatocellular carcinoma after initial hepatectomy: An analysis of patients with resolved hepatitis B virus infection","volume":"24","author":"Bae","year":"2022","journal-title":"HPB"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: Hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"Chen","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105375","DOI":"10.1016\/j.jcv.2022.105375","article-title":"A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays","volume":"160","author":"Wong","year":"2023","journal-title":"J. Clin. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"Kimura","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","article-title":"Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation","volume":"15","author":"Kuo","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jhep.2022.12.017","article-title":"A critique and systematic review of the clinical utility of hepatitis B core-related antigen","volume":"78","author":"Adraneda","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hong, X., Luckenbaugh, L., Mendenhall, M., Walsh, R., Cabuang, L., Soppe, S., Revill, P.A., Burdette, D., Feierbach, B., and Delaney, W. (2021). Characterization of Hepatitis B Precore\/Core-Related Antigens. J. Virol., 95.","DOI":"10.1128\/JVI.01695-20"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.02.017","article-title":"Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation","volume":"75","author":"Inoue","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wang, L., Cao, X., Wang, Z., Gao, Y., Deng, J., Liu, X., and Zhuang, H. (2019). Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients. J. Clin. Microbiol., 57.","DOI":"10.1128\/JCM.01303-18"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","article-title":"Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain","volume":"280","author":"Kimura","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"Wong","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.clinre.2018.10.020","article-title":"Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy","volume":"43","author":"Wang","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Watanabe, T., Inoue, T., and Tanaka, Y. (2021). Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms, 9.","DOI":"10.3390\/microorganisms9102083"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1872-034X.2007.00094.x","article-title":"Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy","volume":"37","author":"Matsumoto","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.hepres.2006.08.005","article-title":"Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection","volume":"36","author":"Shinkai","year":"2006","journal-title":"Hepatol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/jgh.15516","article-title":"Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review","volume":"36","author":"Jaroenlapnopparat","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dkac409","article-title":"Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation","volume":"78","author":"Tseng","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jvh.13528","article-title":"The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients","volume":"28","author":"Huang","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU\/mL","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"(2020). Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol. Res., 50, 892\u2013923.","DOI":"10.1111\/hepr.13504"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cgh.2013.04.010","article-title":"Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: Lessons from experimental and clinical studies","volume":"11","author":"Zoulim","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jvh.13091","article-title":"Can we stop nucleoside analogues before HBsAg loss?","volume":"26","author":"Papatheodoridi","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"Stein","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/infdis\/jiab596","article-title":"Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients","volume":"225","author":"Chen","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jmv.25343","article-title":"Epidemiology, risk factors, and molecular characterization of occult hepatitis B infection among anti-hepatitis B core antigen alone subjects","volume":"91","author":"Azarkar","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e2525","DOI":"10.1002\/rmv.2525","article-title":"Biomarkers of transfusion transmitted occult hepatitis B virus infection: Where are we and what next?","volume":"34","author":"Fu","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"699217","DOI":"10.3389\/fimmu.2021.699217","article-title":"High Frequency Occult Hepatitis B Virus Infection Detected in Non-Resolved Donations Suggests the Requirement of Anti-HBc Test in Blood Donors in Southern China","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/infdis\/jiad140","article-title":"Occult Hepatitis B Virus Infection and Liver Fibrosis in Chinese Patients","volume":"228","author":"Tang","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_72","first-page":"1425","article-title":"Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy","volume":"111","author":"Seto","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cca.2019.10.049","article-title":"HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: \u201cLoss of HBsAg\u201d maybe not a good end-point of anti-viral therapy","volume":"501","author":"Ma","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects","volume":"39","author":"Yuen","year":"2004","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.cgh.2022.07.005","article-title":"Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B","volume":"21","author":"Choi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2023.09.033","article-title":"HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy","volume":"166","author":"Sonneveld","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/4\/529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:20:31Z","timestamp":1760106031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/4\/529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["v16040529"],"URL":"https:\/\/doi.org\/10.3390\/v16040529","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}